March 22, 2024

Abstract 6501: Development and characterization of covalent inhibitors of the RAS-PIK3CA interaction

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Abstract RAS proteins are membrane bound GTPases that when hyperactivated, act as oncogenes through activation of the MAPK Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 6501.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Klebba et al. (Fri,) studied this question.

synapsesocial.com/papers/68e72e40b6db6435876a84e0 https://doi.org/https://doi.org/10.1158/1538-7445.am2024-6501

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract 1954: Development of highly potent, covalent, and selective inhibitors to target PI3Kα in cancer2024
2Abstract 1955: Novel long-acting covalent PI3Kα inhibitors boost potential action in cancer2024
3Abstract A019: Enhancing RAS therapies by targeting PIKfyve in pancreatic cancer2026
4Abstract 3395: Polyisoprenylated cysteinyl amide inhibitors: Effects on RAS signaling pathway intermediates and viability of mutant <i>KRAS</i> African American lung cancer cell line2024
5Abstract 4709: The RASMULTI(ON) inhibitor RMC-7977 blocks downstream MAPK and PI3K pathway activation in KRASG12X_mutant cancers2024 · 1 citations

Preguntar a la IA

Me gusta

Guardar